Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
Journal
The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
03
04
2019
accepted:
26
06
2019
pubmed:
5
7
2019
medline:
31
12
2019
entrez:
5
7
2019
Statut:
ppublish
Résumé
We have shown that the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (Lir) inhibits development of early atherosclerosis in vivo by modulating immune cell function. We hypothesized that Lir could attenuate pre-established disease by modulating monocyte or macrophage phenotype to induce atheroprotective responses. Human atherosclerotic plaques obtained postendarterectomy and human peripheral blood macrophages were treated ex vivo with Lir. In parallel, apolipoprotein E-deficient (ApoE
Identifiants
pubmed: 31270216
pii: jpet.119.258343
doi: 10.1124/jpet.119.258343
doi:
Substances chimiques
Apolipoproteins E
0
Chemokines
0
Inflammation Mediators
0
Liraglutide
839I73S42A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-458Informations de copyright
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.